4United States Pharmacopeial Conventioff.USP[S].Washington:The Board of Trustees,2004,756.
5Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the e- valuation and management of chronic heart failure in the adult: exec- utive summary[J]. J Heart Lung Transplant, 2002, 21(2): 189-203.
7Mohammed EA. High-performance liquid chromatography-mass spectrometric analysis of furosemide in plasma and its use in pharma- cokinetic studies[J]. Ⅱ Farmaco, 2000, 55: 448-454.
8Chi C, Frank JG, Jeffrey RI. LC-MS-Based Metabolomics in Drug Metabolism[J]. Drug metabolism reviews, 2007, 39 (2-3): 581-597.
9Marzo A, Dal BL. Tandem mass spectrometry(LC-MS-MS): a predom- inant role in bioassays for pharmacokinetic studies [J]. Arzneimittel Forschung, 2007, 57: 122-128.
10Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment ofmatrix effect in quantitative bioanalyticalmethods based on HPLC-MS/MS[J]. Anal Chem, 2003, 75 (13): 3019-3030.
